在雄性小鼠的脊柱GABAergic内神经元中通过EZH2-介导的Trpc5抑制来降低吗啡耐受性
Li Wan1,2, Mengyao Zhang1, Haiyue Guo1
1Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|October 20, 2025
概括
重复使用吗啡会减少TRPC5通道,损害疼痛缓解. 激活TRPC5通道与riluzole或基因疗法可以恢复吗啡.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 类阿片类止痛药对于严重的疼痛管理至关重要.
- 对像吗啡这样的阿片类药物的耐受性限制了它们的长期有效性.
- 对阿片类药物耐受性的潜在机制尚未完全理解.
研究的目的:
- 为了研究短暂受体潜能5 (TRPC5) 在吗啡耐受性中的作用.
- 探索TRPC5调制增强阿片类药物止痛的潜力.
- 阐明在吗啡治疗期间调节TRPC5表达的表观遗传机制.
主要方法:
- 在接受了吗啡治疗后,研究了TRPC5表达和功能在脊柱背角 (SDH) 的GABAergic内部神经元中.
- 使用的药理活性剂 (riluzole) 和TRPC5.5的抑制剂.
- 用于TRPC5过度表达和遗传沉默的lentiviral载体.
- 分析了Trpc5基因促进体的表观遗传修饰,使用诸如ChIP-seq.q.这样的技术.
- 在体内评估TRPC5和EZH2调节对吗啡止痛和耐受性的影响.
主要成果:
- 吗啡治疗持续下调SDHGABAergic内部神经元中的TRPC5,损害平衡和GABA释放.
- 脊柱TRPC5激活 (riluzole,过度表达) 增强和延长吗啡的止痛作用.
- 抑制或缺乏TRPC5会加速对吗啡的耐受性.
- 在Trpc5促进体的EZH2-介导表观遗传沉默 (H3K27me3丰富) 抑制了Trpc5的转录.
- 药理或遗传阻断EZH2可以逆转吗啡耐受性.
结论:
- 脊柱GABAergic内部神经元中的TRPC5下调是驱动吗啡耐受性的关键机制.
- 针对TRPC5提供了一种新的策略,以提高阿片类药物的有效性和对抗耐受性.
- 以EZH2为媒介的TRPC5的表观遗传调节对于阿片类药物耐受性发展至关重要.
- 这些发现表明潜在的临床应用,用于治疗难以治愈的疼痛和减少阿片类药物依赖.
更多相关视频
05:24In Vivo SiRNA Transfection and Gene Knockdown in Spinal Cord via Rapid Noninvasive Lumbar Intrathecal Injections in Mice
Published on: March 22, 2014
47.7K
08:16Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
7.6K
相关概念视频
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Opioid Receptors: Overview
4.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.0K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
908
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
908
Opioid Analgesics: Morphine and Other Natural Cogeners
848
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
848
